Antimicrobial potential of Saccharomyces boulardii extracts and fractions

Journal of Applied Sciences Research

Volumn 8, Issue 8, 2012, Pages 4537-4543

  Ali, Maysa A Elsayed ^a   Abdel Fatah, Osama M ^a   Janson, Jan Christer ^b   Elshafei, Ali M ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Active fractions; Antimicrobial activity; Fractionation; Saccharomyces boulardii; Solvent extracts

Indexed keywords

EID: 84872506703     PISSN: 1816157X     EISSN: 1819544X     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Attaie, R., J. Whalen, K.M. Shahani, M.A. Amer, 1987. Inhibition of growth of S. aureus during production of acidophilus yogurt. J. Food Protec., 50: 224-228.
2. Bahgat, M., S. Maghraby Amany, O.M. Abdel-Fatah, A.M. Elshafei, 2005. Immunization of mice with crude extract of Saccharomyces boulardii yeast induces cross-reactive immune responses with antigenic preparations from different developmental stages of the Schistosoma mansoni and reduces the parasite worm burden. J. Egypt. Soc. of Parasit, 35(2): 563-580.
3. Brandão, R.L., I.M. Castro, E.A. Bambirra, S.C. Amaral, L.G. Fietto, M.J. Tropia, M.J. Neves, R.G. Dos Santos, N.C. Gomes, J.R. Nicoli, 1998. Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae. Appl. Environ. Microbiol., 64: 564-568.
4. Buts, J.P., P. Bernasconi, M.P. Van Craynest, P. Maldague, R. De Meyer, 1986. Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatrics Res., 20(2): 192-196.
5. Buts, J.P., D.N. Keyser, D.L. Raedemaeker, 1994. Saccharomyces boulardii enhances rat intestinal enzyme expression of endoluminal release of polyamines. Pediatrics Res., 36: 552-527.
6. Castagliuolo, I., M.F. Riegler, L. Valenick, J.T. LaMont, C. Pothoulakis, 1999. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 67(1): 302-307.
7. Cetina, S.G., B.G. Siemo, 1999. Evaluation therapeutique de saccharomyces chez des enfants sourffrant de diarrhea aigue. Annal. de Pediatr, 41: 397-400.
8. Czerucka, D., S. Dahan, B. Mograbi, B. Rossi, P. Rampal, 2000. Saccharomyces boulardii Preserves the Barrier Function and Modulates the Signal Transduction Pathway Induced in Enteropathogenic Escherichia coli- Infected T84 Cells. Infect. and Immun., 68(10): 5998-6004.
9. Czerycka, D., P. Rampal, 2002. Experimental effect of Saccharomyces boulardii on diarrheal pathogens. Microb. and infect., 4: 733-739.
10. Elshafei, A.M., S.S. Mahmoud, S.A. Ahmed, A. El-Ansary, 2007. A parasitological study on the use of biotherapeutic yeast in the treatment of Schistosoma mansoni infected mice. Egypt Pharm J (NRC), 6(1): 47-56.
11. Gedek, B.R., 1999. Adherence of Escherichia coli serogroup O 157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii Mycoses, 42(4): 261-264.
12. Gionchetti, P., F. Rizzello, A. Venturi, P. Brigidi, D. Matteuzzi, G. Bazzocchi, 2000. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo controlled trial Gastroenterology, 119: 305-9.
13. Guslandi, M., G. Mezzi, M. Sorghi, P.A. Testoni, 2000. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Digestive Diseases and Sciences, 45: 1462-1464.
14. Izadnia, F., C.T. Wong, A. Samuel, M.D. Kochoshis, 1998. Brewer's yeast and Saccharomyces boulardii both attenuate Clostridium difficile -induced colonic secretion in the rat. Diges Dis Sci., 43(90): 255-2060.
15. Kenney, J.F. and E.S. Keeping, 1962. "The Standard Deviation" and "Calculation of the Standard Deviation." §6.5-6.6 in Mathematics of Statistics, Pt. 1, 3rd ed. Princeton, NJ: Van Nostrand. pp: 77-80.
16. Krasowska, A., A. Murzyn, A. Dyjankiewicz, M. Lukaszewicz, D. Dziadkowiec, 2009. The antagonistic effect of Saccharomyces boulardii on Candida albicans filamentation, adhesion and biofilm formation. FEMS Yeast Resear, 9(8): 1312-1321.
17. Kruis, W., E. Schutz, P. Fric, B. Fixa, G. Judmaiier, M. Stolte, 1997. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics, 11: 853-8.
18. Martins, F.S., R.M.D. Nardi, R.M.E. Arantes, C.A. Rosa, M. Neves, J.R. Nicoli, 2005. Screening of yeasts as probiotic based on capacities to colonize the gastrointestinal tract and to protect against enteropathogen challenge in mice. J.Gen.Appl.Microbiol., 51: 83-92.
19. McFarland, L.V., C.M. Surawics, R.N. Greenberg, G.W. Elmer, K.A. Moyer, S.A. Melcher, 1995. Prevention of b-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. American Journal of Gastroenterology, 90: 439-48.
20. McFarland, L.V., C.M. Surawicz, R.N. Greenberg, R. Fekety, G.W. Elmer, K.A. Moyer, 1994. A randomized placebo controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. Journal of the Amer. Med. Assoc., 271: 1913-1918.
21. Murzyn, A., A. Krasowska, D. Augustyniak, G. Majkowska-Skrobek, M. Lukaszewicz, D. Dziadkowiec, 2010b. The effect of Saccharomyces boulardii on Candida albicans-infected human intestinal cell lines Caco-2 and Intestin 407. FEMS Microbiol. Lett., 310(1): 17-23.
22. Murzyn, A., A. Krasowska, P. Stefanowicz, D. Dziadkowiec, M. Lukaszewicz, 2010a. Capric Acid Secreted by S. boulardii Inhibits C. albicans Filamentous Growth, Adhesion and Biofilm Formation. PLoS One. 2010; 5(8): e12050. Published online 2010 August 10. doi: 10.1371/journal.pone.0012050.
23. Rodrigues, C.P., D.C. Cara, S.H.G.G. Fretez, F.Q. Cunha, E.C. Vieria, J.R. Nicoli, A.L.Q. Vieir, 2000. Saccharomyces boulardii stimulates sIgA production and the phagocytic system of gnotobiotic mice. J of Appl. Microbiol., 89: 404-414.
24. Roos, K., E. Grahn Håkansson, S. Holm, 2001. Effect of recolonisation with 'interfering' a streptococci on recurrences of acute and secretory otitis media in children: randomised placebo controlled trial. Brit. Med. J., 322: 1-4.
25. Rosenfeldt, V., E. Benfeldt, N.H. Valerius, A. Paerregaard, K.F. Michaelsen, 2004. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. J Pediatr 145: 612-616.
26. Satyajit, S., L. Zahid, G. Alexander, 2006. "Natural Product Isolation: Second Edition". Methods in Biotechnology. HUMANA Press, Totowa, NJ.
27. Sullivan, A., C.E. Nord, 2002. Probiotics in human infections. Journal of Antimicrobial Chemotherapy, 50: 625-627.
28. Surawicz, C.M., G.W. Elmer, P. Speelman, L.V. McFarland, S. Chinn, G. Van, 1989. Prevention of antibiotic associated diarrhea by Saccharomyces boulardii A perspective study. Gastroenterol., 96: 981-988.
29. Warburg, O., W. Christian, 1942. Isolation and crystallization of enolase. Biochem. Z., 310: 384-421.
30. Zaouche, A., C. Loukil, P. De Lagausie, 2000. Effects of oral Saccharomyces boulardii on bacterial overgrowth, translocation, and intestinal adaptation after small-bowel resection in rats. Scand J Gastroenterol., 35(2): 160-165.